Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
| Revenue (Most Recent Fiscal Year) | $1.83B |
| Net Income (Most Recent Fiscal Year) | $-440.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 10.17 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -23.71% |
| Net Margin (Trailing 12 Months) | -24.08% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -12.18% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.08 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.98 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.52 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.56 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 125.95M |
| Free Float | 124.06M |
| Market Capitalization | $18.60B |
| Average Volume (Last 20 Days) | 0.52M |
| Beta (Past 60 Months) | 0.39 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.97% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |